Home › Trial NCT04904185
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
- Trial IDNCT04904185
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorInge Marie Svane
- Enrollment8
- Start date2021-09-17
- ConditionsMalignant Melanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.